Masimo (NASDAQ: MASI) previews 2025 results, JPM conference session
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Masimo Corporation filed an 8-K describing how it is sharing early views of its recent performance. On January 12, 2026, the company issued a press release with select preliminary financial results for the fourth quarter and full year ended January 3, 2026, with full audited figures to follow.
Management plans to review complete fourth quarter and full-year 2025 results after the market closes on February 26, 2026. On the same day as the filing, the CEO and EVP & CFO discussed select preliminary results at the 44th Annual J.P. Morgan Healthcare Conference, and Masimo also made available a supplemental 2025 earnings presentation and non-GAAP information as furnished exhibits.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 2.02, 7.01, 9.01
3 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________
FORM 8-K
________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 12, 2026
(Exact name of registrant as specified in its charter)
________________________________________________
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||||||||||||||||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||||||||||||||||||||||||||
Registrant’s telephone number, including area code: | ||||||||||||||||||||||||||||||||
Not Applicable | ||||||||||||||||||||||||||||||||
(Former name or former address, if changed since last report) | ||||||||||||||||||||||||||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | |||||
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Securities Registered pursuant to Section 12(b) of the Act: | |||||||||||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | |||||||||||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |||||||||||||||||
| Emerging growth company | |||||||||||||||||
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ | ||||||||||||||||
| Item 2.02. | Results of Operations and Financial Condition. | ||||
On January 12, 2026, Masimo Corporation (the “Company”) issued a press release announcing select preliminary financial results for the fourth quarter and full-year ended January 3, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report. The preliminary financial information presented in this press release is based on the Company’s current expectations and may be adjusted as a result of, among other things, completion of customary annual audit procedures. The Company’s management plans to discuss the Company’s complete fourth quarter and full-year 2025 financial results after the market closes on Thursday, February 26, 2026.
In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 7.01. | Regulation FD Disclosure. | ||||
In connection with the Company’s participation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, the Company’s Chief Executive Officer and EVP, Chief Financial Officer, will review select preliminary financial results for the fourth quarter and full-year 2025.
In addition, the Company is making available to investors supplemental financial information for fiscal 2025, as well as a discussion of non-GAAP measures, adjustments and definitions pursuant to the materials furnished as Exhibit 99.2 to this Current Report.
In accordance with General Instructions B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01. | Financial Statements and Exhibits. | ||||
(d) The following items are filed as exhibits to the Current Report on Form 8-K.
Exhibit No. | Description | ||||
| 99.1 | Press Release, Dated January 12, 2025, Reporting Select Preliminary 2025 Financial Results | ||||
| 99.2 | Masimo 2025 Supplemental Earnings Presentation | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, Masimo Corporation has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
MASIMO CORPORATION | ||||||||||||||||||||||||||
Date: January 12, 2026 | By: | /s/ MICAH YOUNG | ||||||||||||||||||||||||
| Micah Young | ||||||||||||||||||||||||||
| Executive Vice President & Chief Financial Officer | ||||||||||||||||||||||||||
| (Principal Financial Officer) | ||||||||||||||||||||||||||
FAQ
What did Masimo (MASI) disclose in this 8-K filing?
Masimo disclosed that it issued a press release with select preliminary financial results for the fourth quarter and full year ended January 3, 2026, and furnished related investor materials.
Which periods do Masimo’s preliminary results cover in this update?
The preliminary financial results cover the fourth quarter and full-year 2025, for the period ended January 3, 2026.
When will Masimo report its complete fourth quarter and full-year 2025 results?
Masimo’s management plans to discuss complete fourth quarter and full-year 2025 financial results after the market closes on February 26, 2026.
What exhibits did Masimo include with this 8-K filing?
Masimo included a press release reporting select preliminary 2025 financial results (Exhibit 99.1), a 2025 supplemental earnings presentation (Exhibit 99.2), and the cover page interactive data file (Exhibit 104).
How is Masimo sharing information at the J.P. Morgan Healthcare Conference?
At the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, Masimo’s CEO and EVP, Chief Financial Officer, reviewed select preliminary fourth quarter and full-year 2025 financial results.
Are Masimo’s preliminary financial results in this 8-K considered filed with the SEC?
The company notes that the information furnished under Items 2.02 and 7.01 is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not automatically incorporated by reference into Securities Act or Exchange Act filings.